Abstract 934P
Background
The purpose of the study was to analyze the endocrine status of patients with Hodgkin lymphoma (HL) before treatment and the effect of chemotherapy on sex, pituitary and glucocorticoid hormones.
Methods
Gonadal function, its regulation by tropic pituitary hormones and levels of prolactin and cortisol were studied by radioimmunoassay in 32 HL patients aged 12-21 years receiving chemotherapy.
Results
Before therapy females showed estradiol decreased by 10 times compared with the norm in follicular and luteal phases of the cycle, with testosterone increase by 3.7 times in phase I and by 10 times in phase II of the cycle. Follicle-stimulating hormone (FSH) was 10 times lower than the norm. Luteinizing hormone in the luteal phase was similar to the norm in all disease stages, and in the follicular phase it was decreased by 15 times in patients with stage III-IV disease, compared with the norm. Male patients, especially those with stage III-IV disease, showed low testosterone levels in the blood before treatment. Significant overproduction of estradiol was observed, especially in stages III-IV. FSH levels in stage III-IV patients were 11 times lower than the norm; cortisol content did not change in stages I-II, and in stages III-IV it was 2.5 times higher than the norm. Prolactin and progesterone levels were similar to the norm.
Conclusions
HL development in adolescents is accompanied by significant changes in levels of sex and pituitary hormones and cortisol depending on the disease stage. Chemotherapy provides high antitumor effect and normalizes the levels of circulating hormones that have changed before the treatment.
Clinical trial identification
Legal entity responsible for the study
Rostov Research Institute of Oncology
Funding
Ministry of Health of the Russian Federation
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract